Paper Details

  1. Home
  2. Paper Details

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.

Author: HibiT, IidaM, MatsuiT, NakamuraM, OgataH, SuzukiY, TakazoeM

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Oral tacrolimus was effective and safe for remission-induction therapy of refractory UC. The optimal target range appears to be 10-15 ng/ml in terms of efficacy with two week therapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860021/

データ提供：米国国立医学図書館（NLM）

Oral Tacrolimus: A Promising Therapy for Refractory Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that can be difficult to manage. This study investigates the efficacy and safety of oral tacrolimus, an immunosuppressant medication, in treating refractory UC. The researchers conducted a randomized, controlled trial to assess the effectiveness of different tacrolimus dosages in inducing remission in patients with refractory UC.

Dose-Dependent Efficacy of Oral Tacrolimus in Refractory UC

The study demonstrated a dose-dependent efficacy of oral tacrolimus in inducing remission in patients with refractory UC. The researchers observed significant improvements in disease activity scores in patients receiving higher tacrolimus doses. These findings suggest that oral tacrolimus may be a valuable therapeutic option for patients with refractory UC.

Finding Relief: Managing Refractory Ulcerative Colitis

This study offers hope for patients with refractory UC, highlighting the potential of oral tacrolimus for inducing remission. The findings provide valuable information for clinicians seeking effective treatment options for this challenging condition.

Dr. Camel's Conclusion

This study presents compelling evidence for the efficacy of oral tacrolimus in treating refractory UC. The researchers demonstrated a dose-dependent effect, suggesting that careful dose optimization is crucial for achieving optimal therapeutic outcomes.

Date :
  1. Date Completed 2006-09-21
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

16484504

DOI: Digital Object Identifier

PMC1860021

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.